Skip to content
Screener

Stoke Therapeutics, Inc. STOK Other income, net (Note 6)

Other income, net (Note 6) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$987K+868%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$13.18M+167%
CalAmp logo
CalAmpCAMP
$18K-77.2%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
-$127K+54.0%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$31K-10.7%
Maze Therapeutics logo
Maze TherapeuticsMAZE
$2.35M-10.3%

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$2.06B+187%
Enterprise value$1.91B+206%
P/S64.2×+60.6×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0.0×
Current ratio+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211874
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
(Loss) income from operations(53,418)111,240
Other income (expense):
Interest income (expense), net3,3972,889
Other income1828
Total other income (expense)3,4152,917
(Loss) income before income taxes$(50,003)$114,157
Provision for income taxes1,278
Net (loss) income$(50,003)$112,879

Item 1. Financial Statements.

FAQ

What is Stoke Therapeutics, Inc.'s other income, net (note 6)?
Stoke Therapeutics, Inc. (STOK) reported other income, net (note 6) of $18K in Q1 2026.
How has Stoke Therapeutics, Inc.'s other income, net (note 6) changed year-over-year?
Stoke Therapeutics, Inc.'s other income, net (note 6) decreased by 35.7% year-over-year, from $28K to $18K.
What is the long-term trend for Stoke Therapeutics, Inc.'s other income, net (note 6)?
Over 3 years (2021 to 2025), Stoke Therapeutics, Inc.'s other income, net (note 6) has grown at a -28.6% compound annual growth rate (CAGR), from $140K to -$51K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Stoke Therapeutics, Inc.'s other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude